This article compares published clinical trial data from separate trials with different designs. Cross-trial comparisons are approximate — they are not a substitute for direct head-to-head data. This article is for educational purposes only.

⚠ Investigational Drug — Not FDA-Approved

Retatrutide is not FDA-approved as of June 2026. Mounjaro (tirzepatide) is FDA-approved for type 2 diabetes; Zepbound (tirzepatide) is FDA-approved for chronic weight management. The comparison in this article is based on separate clinical trials that cannot be directly compared without the caveat that population, endpoint, and duration differences affect outcomes.

Before comparing retatrutide to Mounjaro, the most important clarification: Mounjaro and Zepbound are the same drug. Both contain tirzepatide. Mounjaro is approved for type 2 diabetes; Zepbound is approved for chronic weight management. Mounjaro's diabetes trials (SURPASS program) showed less weight loss than Zepbound's obesity trials (SURMOUNT program) — not because the drug is different, but because people with type 2 diabetes consistently lose less weight on GLP-1 class drugs than people without diabetes.

This distinction matters enormously for any comparison with retatrutide. Mounjaro's SURPASS-2 trial weight-loss numbers (~12–13%) reflect a diabetic population. A comparison between retatrutide's TRIUMPH-1 and Mounjaro's SURPASS-2 would be comparing an obesity drug trial to a diabetes drug trial — apples to oranges. The relevant comparison for most readers is retatrutide vs. tirzepatide in obesity populations without diabetes. For that comparison, see our dedicated article on tirzepatide vs. retatrutide weight loss.

Understanding Mounjaro and Zepbound: Same Drug, Different Indications

Tirzepatide (brand name Mounjaro for T2D, Zepbound for obesity) was developed by Eli Lilly and is a first-in-class GLP-1/GIP dual hormone receptor agonist. Both Mounjaro and Zepbound use the same tirzepatide molecule at the same doses (2.5, 5, 7.5, 10, 12.5, and 15 mg weekly). The molecules, the pens, and the dose escalation schedule are identical. The FDA approved them for different indications under different brand names.

Clinical context is critical:

  • Mounjaro (tirzepatide, T2D indication): SURPASS-2 trial showed mean weight loss of ~12–13% at 15 mg over 40 weeks. SURPASS-1 showed similar results. These are from people with type 2 diabetes who are not obese by obesity-trial standards.
  • Zepbound (tirzepatide, obesity indication): SURMOUNT-1 showed mean weight loss of 20.9% at 15 mg over 72 weeks. SURMOUNT-2 (in people with obesity and T2D) showed 15.7% at 15 mg — confirming the diabetes-population effect.

When people ask "retatrutide vs. Mounjaro," they are almost always asking about the weight-loss comparison in the obesity context. That comparison requires using tirzepatide's SURMOUNT-1 data (20.9% at 72 weeks) as the reference point, not the Mounjaro SURPASS trials (12–13%).

Mechanism: Triple vs. Dual Agonism

The fundamental pharmacological difference between retatrutide and tirzepatide (Mounjaro/Zepbound) is the addition of glucagon receptor activation:

  • Tirzepatide (Mounjaro/Zepbound): GLP-1 + GIP dual agonist. Appetite suppression (GLP-1), enhanced metabolic effects (GIP), reduced nausea relative to GLP-1 alone (GIP).
  • Retatrutide: GLP-1 + GIP + glucagon triple agonist. All of the above, plus thermogenesis via brown adipose tissue (glucagon), and direct hepatic fat oxidation (glucagon).

The glucagon component is what allows retatrutide to produce greater weight loss at a shorter or comparable endpoint: it adds energy expenditure to appetite suppression. Tirzepatide primarily works on the intake side of the energy equation; retatrutide works on both sides. For a full explanation of the mechanism, see our article on triple agonist weight loss drugs.

Weight Loss Comparison: Trial Data Side by Side

This comparison uses the obesity-indication populations only — the most clinically relevant comparison for people considering weight management treatment:

Tirzepatide in Obesity (SURMOUNT-1)

  • Population: 2,539 adults with obesity (BMI ≥30) or overweight with comorbidities, without type 2 diabetes
  • Endpoint: 72 weeks
  • Maximum dose: 15 mg weekly
  • Mean weight loss at 15 mg: 20.9% (~52 lbs from a ~100 kg baseline)
  • Participants achieving ≥20% weight loss at 15 mg: approximately 57%
  • Participants achieving ≥30% weight loss at 15 mg: approximately 28%

Retatrutide in Obesity (TRIUMPH-1)

  • Population: 2,339 adults with obesity (BMI ≥30) or overweight with comorbidities, without type 2 diabetes
  • Endpoint: 80 weeks
  • Maximum dose: 12 mg weekly (with 4 mg and 9 mg arms)
  • Mean weight loss at 12 mg: 28.3% (~70.3 lbs from a ~112.7 kg baseline)
  • Participants achieving ≥25% weight loss at 12 mg: 62.5%
  • Participants achieving ≥30% weight loss at 12 mg: 45.3%

Key Observations from the Data

The 8-week endpoint difference (80 vs. 72 weeks) and the 12.7 kg (28 lb) difference in mean baseline weight between the trials mean this is not a clean comparison. Heavier patients tend to lose more absolute weight on percentage-based dosing protocols, which could partially explain the higher mean weight loss in TRIUMPH-1. However, several observations are robust to these limitations:

  • The 30% responder rate is nearly double: 45.3% vs. ~28% at the highest dose. This difference is too large to be explained by the 8-week endpoint difference or baseline weight differences alone.
  • Retatrutide's lower dose outperforms tirzepatide's lower dose: Retatrutide 4 mg produced 19.0% at 80 weeks. Tirzepatide 5 mg produced approximately 15% at 72 weeks. The dose-response advantage favors retatrutide even at comparable dose levels.
  • The efficacy gap is maintained even accounting for endpoint differences: Cross-trial modeling suggests that retatrutide at 72 weeks would have shown approximately 26–27% weight loss — still substantially greater than tirzepatide's 20.9% at the same timepoint.

Mounjaro Weight Loss in Type 2 Diabetes: A Critical Clarification

When searching "Mounjaro weight loss" or "Mounjaro vs. retatrutide," many results mix the T2D trial numbers with the obesity trial numbers. This comparison table clarifies which numbers apply to which population:

Tirzepatide in type 2 diabetes (SURPASS trials):

  • SURPASS-2: 15 mg, 12–13% weight loss at 40 weeks (T2D population)
  • SURPASS-3: 15 mg, ~13.4% weight loss at 52 weeks (T2D population)

Tirzepatide in obesity without T2D (SURMOUNT trials):

  • SURMOUNT-1: 15 mg, 20.9% weight loss at 72 weeks (obesity population)
  • SURMOUNT-2: 15 mg, 15.7% weight loss at 72 weeks (obesity + T2D population)

Retatrutide's TRIUMPH-1 (obesity without T2D, 80 weeks at 12 mg: 28.3%) is the appropriate comparator to SURMOUNT-1, not to the Mounjaro SURPASS data. Comparing retatrutide TRIUMPH-1 to Mounjaro SURPASS-2 would inflate the apparent advantage by comparing obesity-population to diabetes-population outcomes.

Safety Comparison

Tirzepatide (SURMOUNT-1)

  • Nausea: ~25–30% at 15 mg
  • Diarrhea: ~17–22% at 15 mg
  • Vomiting: ~8–12% at 15 mg
  • Discontinuation due to adverse events: approximately 7% at 15 mg
  • No dysesthesia signal
  • No UTI signal above placebo

Retatrutide (TRIUMPH-1)

  • Nausea: 42.4% at 12 mg; lower at 4 mg and 9 mg
  • Diarrhea: 32.0% at 12 mg
  • Vomiting: 25.3% at 12 mg
  • Constipation: 26.1% at 12 mg
  • Discontinuation: 4.1% (4 mg), 6.9% (9 mg), 11.3% (12 mg) vs. 4.9% placebo
  • Dysesthesia: ~12.5% at 12 mg (glucagon-specific; not seen with tirzepatide)
  • UTI signal: 7.5–8.8% vs. 5.3% on placebo

At the highest doses, retatrutide has higher GI event rates and discontinuation rates than tirzepatide. However, retatrutide's 4 mg dose has a better tolerability profile than any tirzepatide dose studied — with fewer discontinuations than placebo. The safety comparison is meaningfully dose-dependent. Patients who can tolerate 12 mg retatrutide experience more side effects for substantially more weight loss. Patients who stabilize at 4 mg experience fewer side effects than many tirzepatide users while achieving 19% weight loss.

The TRIUMPH-5 Head-to-Head Trial

One of the most important pending datasets in obesity pharmacology is the TRIUMPH-5 Phase 3 trial, which directly compares retatrutide against tirzepatide in a randomized, head-to-head design. TRIUMPH-5 is actively enrolling as of June 2026, with results expected approximately December 2026.

A head-to-head trial controls for the major methodological concerns in cross-trial comparisons: population differences, endpoint timing, baseline weight, concomitant interventions, and statistical methodology. TRIUMPH-5 data will be the definitive evidence for which drug produces superior weight loss and what the safety trade-offs are when both are available.

The fact that Lilly is running a trial comparing its own drugs against each other is notable — it suggests confidence that retatrutide will win the comparison, as a drug maker does not typically pay for a head-to-head trial that will show its new drug is inferior. If TRIUMPH-5 confirms the cross-trial advantage, it substantially strengthens the case for retatrutide as the preferred option for patients who can tolerate higher-dose escalation.

Cardiovascular Outcomes: What We Know

Tirzepatide's cardiovascular outcomes data: the SURMOUNT-MMO trial is evaluating cardiovascular outcomes in people with obesity. Results are expected in 2026–2027. Earlier SURPASS-CVOT data showed tirzepatide non-inferiority for cardiovascular safety in T2D, but a dedicated cardiovascular outcomes efficacy trial comparable to semaglutide's SELECT is ongoing.

Retatrutide's cardiovascular outcomes: TRIUMPH-Outcomes (NCT06383390), with approximately 10,000 participants, is the long-running cardiovascular outcomes trial. It is not expected to report until approximately 2028. Cardiometabolic risk factor improvements in TRIUMPH-1 (41% triglyceride reduction, 24.2% non-HDL cholesterol reduction, 12.3 mmHg systolic BP reduction) are favorable indicators, but hard MACE event data will not be available before approval.

For patients with established cardiovascular disease, the currently available SELECT trial data for semaglutide (26% cardiovascular risk reduction in MACE) remains the strongest cardiovascular evidence in the class. The TRIUMPH-3 trial (obesity + CVD) will eventually provide data on whether retatrutide reduces cardiovascular events in that population. Results expected 2026–2027.

Practical Considerations for Patients

For patients currently on Mounjaro for T2D or Zepbound for obesity, retatrutide's data raise several questions that will not have definitive answers until approval and real-world prescribing experience develops:

Will retatrutide be prescribed instead of Mounjaro for T2D? Retatrutide's TRANSCEND-T2D-1 data showed HbA1c reductions of 1.7–2.0 percentage points and 11.5–16.8% weight loss in T2D patients — competitive with Mounjaro. If approved for T2D, retatrutide will offer greater weight loss at the cost of more side effects. For T2D patients with obesity who need aggressive weight reduction alongside glycemic control, retatrutide may offer a superior option.

Will patients switch from Zepbound to retatrutide? Patients who are losing weight successfully on tirzepatide have little immediate reason to switch — retatrutide is not approved and changing therapies always carries uncertainty. However, patients who have reached a plateau on tirzepatide, or who need more than 20% weight loss, will have a compelling clinical case for transitioning when retatrutide becomes available. No data on switching from tirzepatide to retatrutide exists; clinical guidance will emerge in the years following retatrutide's approval.

For more context on Mounjaro vs. Zepbound — the same molecule for different indications — see our article on Mounjaro vs. Zepbound. For the broader weight-loss comparison including trial methodology discussion, see tirzepatide vs. retatrutide weight loss.

Independent Analysis: Three Comparison Points Worth Noting

The following three observations about the retatrutide vs. Mounjaro/tirzepatide comparison receive insufficient attention in mainstream coverage:

1. The commercial competition between these drugs benefits patients, not just Lilly

Lilly will be in the unusual position of competing with itself: Mounjaro/Zepbound (tirzepatide) versus future retatrutide. Pharmaceutical companies rarely introduce a drug that cannibalizes their existing blockbuster. Lilly is doing so because the revenue opportunity from retatrutide exceeds the cost of Zepbound cannibalization, but the competitive dynamic also creates pricing pressure that benefits patients. If Lilly prices retatrutide significantly above tirzepatide without commensurate access improvement, prescribers will stick with Zepbound. If they price them comparably, formulary competition between the two may actually reduce both drugs' prices over time.

2. The "right" drug for a given patient depends on more than efficacy magnitude

A patient who needs 25% weight loss to achieve diabetes remission may find retatrutide clearly superior. A patient who needs 15% weight loss to meaningfully improve hypertension and joint pain may find Zepbound perfectly adequate — and prefer its better-characterized long-term safety profile (years of real-world data vs. months post-approval for a new drug). The clinical decision is not simply "which drug produces more weight loss" but "which drug produces sufficient weight loss for this patient's clinical goals with acceptable tolerability."

3. The 4 mg retatrutide dose is essentially a new drug compared to existing options

Retatrutide 4 mg — producing 19% weight loss with sub-placebo discontinuation rates — has no meaningful equivalent in currently approved therapy. Tirzepatide at its minimum clinically useful doses (5–7.5 mg) produces approximately 12–15% weight loss with higher GI event rates than retatrutide 4 mg at the same timepoint. For patients who have struggled with tolerability on existing GLP-1 drugs, the 4 mg retatrutide dose may become the most clinically appealing entry point — offering better weight loss than anything currently available while having one of the best tolerability profiles in the class.

Frequently Asked Questions

What is the difference between retatrutide and Mounjaro?

Mounjaro contains tirzepatide, a dual GLP-1/GIP agonist FDA-approved for type 2 diabetes. Retatrutide is an investigational triple agonist (GLP-1 + GIP + glucagon) not yet approved. In obesity populations, retatrutide's TRIUMPH-1 produced 28.3% weight loss versus tirzepatide's SURMOUNT-1 at 20.9%. In T2D populations, Mounjaro produces 12–15% weight loss.

Is Mounjaro and Zepbound the same drug as tirzepatide?

Yes. Both Mounjaro and Zepbound contain tirzepatide as the active ingredient. Mounjaro is the T2D brand (approved 2022); Zepbound is the obesity brand (approved 2023). Same molecule, same doses, same escalation schedule — different indications and branding.

Why is comparing retatrutide vs Mounjaro difficult?

The trials were conducted in different populations (Mounjaro's SURPASS trials: T2D patients; Retatrutide's TRIUMPH-1: obesity without T2D), at different endpoints (72 vs. 80 weeks), and with different baseline weights. Cross-trial comparisons can only be approximate. The TRIUMPH-5 head-to-head trial will provide direct data.

Is there a head-to-head trial of retatrutide vs tirzepatide?

Yes. TRIUMPH-5 is an active Phase 3 head-to-head trial comparing retatrutide vs. tirzepatide directly. It is actively enrolling as of June 2026 with results expected approximately December 2026.

Does Mounjaro produce more weight loss in diabetes patients than Zepbound does in obesity patients?

No — the opposite. Mounjaro's SURPASS trials (T2D patients) showed ~12–13% weight loss at 15 mg. Zepbound's SURMOUNT-1 (obesity without T2D) showed 20.9%. People with T2D consistently lose less weight on GLP-1 drugs due to counter-regulatory hormonal factors.

Will retatrutide replace Mounjaro when approved?

Retatrutide will likely be a premium option for patients needing greater weight loss. Mounjaro/Zepbound will remain relevant for patients who tolerate it well, for whom 20% loss is sufficient, or who cannot tolerate retatrutide's higher-dose side effects. The drugs will coexist serving different patient needs.

What does Mounjaro cost compared to retatrutide?

Mounjaro's list price is approximately $1,000–$1,100/month as of 2026, though most commercially insured patients pay less through savings cards. Retatrutide pricing has not been announced — it is not yet approved. Based on Lilly pricing precedents, it may carry a similar or higher list price, with access depending on insurance coverage.

Sources

  1. Jastreboff AM, et al. "Triple–Hormone-Receptor Agonist Retatrutide for Obesity — Phase 2 Trial." NEJM, 2023. https://www.nejm.org/doi/full/10.1056/NEJMoa2301972
  2. Eli Lilly. TRIUMPH-1 Phase 3 Topline Results. May 21, 2026. https://www.cnbc.com/2026/05/21/eli-lilly-weight-loss-drug-retatrutide-clears-obesity-trial.html
  3. Wilding JPH, et al. "Tirzepatide Once Weekly for the Treatment of Obesity (SURMOUNT-1)." NEJM, 2022. https://www.nejm.org/doi/full/10.1056/NEJMoa2206038
  4. Frías JP, et al. "Tirzepatide versus Semaglutide Once Weekly in Patients with Type 2 Diabetes (SURPASS-2)." NEJM, 2021. https://www.nejm.org/doi/full/10.1056/NEJMoa2107519
  5. Medscape. "Retatrutide Data Show Dramatic Weight Loss, Other Benefits." ADA 2026. https://www.medscape.com/viewarticle/retatrutide-data-show-dramatic-weight-loss-other-benefits-2026a1000iz0
  6. Clinical Trials Arena. "Lilly's 'triple G' agonist triumphs in Phase III trial." May 22, 2026. https://www.clinicaltrialsarena.com/news/eli-lilly-retatrutide-phase-iii-triumph-1-study-results/